The biotechnology company Oxolife has initiated a triple internacional collaboration with the Energy Balance, Puberty and Reproductive Health research group of the University of Cordoba (UCO, Spain) and the Human Growth and Reproductive Development research group at Rutgers, The State University of New Jersey. The main objective is to further investigate the direct mechanisms of the drug OXO-001, designed to improve embryo implantation and to treat infertility associated with Polycystic Ovary Syndrome (PCOS).
Oxolife, a CataloniaBio & HealthTech member, is developing OXO-001, an innovative and pioneering drug for reproductive medicine. Oxolife has already initiated a Phase II clinical trial with the drug to demonstrate its efficacy in improving embryo implantation in women with infertility. For its use to treat infertility associated with PCOS, the drug is in preclinical studies. In order to obtain more information about the mechanism of action of OXO-001 and its potential use as a treatment for infertility associated with PCOS, Oxolife has initiated this international collaboration.
According to Ignasi Canals, CSO at Oxolife, this collaboration between the three entities “involves a partnership between biotech companies and research centers and it enables to leverage the experience and knowledge of pioneering centers in order to accelerate the drug development process to bring medical solutions to patients."
Comments